Where is JLABS's headquarters located?

JLABS's headquarters is located in San Diego (United States).

How many companies has JLABS invested in?

JLABS has invested in 355 companies, including Huma & Eko.

How many exits has JLABS been involved in?

JLABS's portfolio has seen 17 IPOs and 31 acquisitions.

How many unicorns are there in JLABS's portfolio?

There is 1 unicorn in JLABS's portfolio.

JLABS - 2026 Investor Profile, Portfolio, Team & Investment Trends

JLABS is an accelerator and incubator program based in San Diego, United States. With a presence in 22 countries, it has supported around 355 startups in sectors like Life Sciences, HealthTech. As of Apr 2026, JLABS has 1 unicorn under its belt and has witnessed 48 portfolio exits. Most notable companies in its portfolio include Huma, Eko and Strand Therapeutics. The program is backed by a team of 10 people who primarily support Series A startups based in Belgium. Its latest investment was a $21.1M Series A round in Syndesi Therapeutics on Feb 01, 2018, which also saw participation from Novo Holdings and Fountain Healthcare Partners.

Key Metrics

Location

San Diego, United States

Portfolio Companies

Huma, Eko & 353 more

Sectors of Investment

Life Sciences, HealthTech & 18 more

Stages of Investment

Series A

Locations of Investment

United States, Canada & 20 more

Unicorn in Portfolio

Mammoth

View JLABS's full profile

JLABS has a portfolio of 355 companies, one of which is a Unicorn. Their most notable investments include Huma and Eko.Their portfolio spans across United States, Canada, China and 19 more locations. They have invested in Life Sciences, HealthTech, High Tech and 17 other sectors, across stages such as Series A stage. Here is the list of top investments by JLABS:

1. Huma

Provider of suite of apps for patients and doctors. The products are remote patient monitoring, mental health digital medicine, blood pressure monitoring app. Medopad has created a COVID-19 specific remote patient monitoring app and healthcare provider telemedicine portal. Biobeats are an app and wearable device measures health data such as heart rate variability, sleep patterns, activity, and mood are collected in realtime for employees. It provides continuous blood pressure monitoring without a cuff.

Key facts about Huma

Founded Year: 2011
Location: London (United Kingdom)
Valuation: $*****
Stage: Series D
Total Funding till date: $355M
Employee Count: 273 as on Mar 31, 2026
Investors: Nomura, Samsung NEXT and 98 Others
Latest Funding Round: Series D, Apr 25, 2025, $*****
Highlight: Editors' Pick

2. Eko

Eko offers an AI-based platform for remote monitoring of cardiac health. The solution offered by the company collects real-time patient data and analyses it to generate a report for doctors. The report generated aids in providing proper treatment to patients. The company has also developed products like Duo and Core stethoscopes for heart disease monitoring.

Key facts about Eko

Founded Year: 2012
Location: Oakland (United States)
Stage: Series D
Total Funding till date: $195M
Employee Count: 203 as on Mar 31, 2026
Investors: 10x Group, Artis Ventures and 33 Others
Latest Funding Round: Grant (prize money), Apr 11, 2025, $*****
Highlight: Editors' Pick

3. Strand Therapeutics

Provider of a platform to deliver mRNA therapeutics for multi-functional treatments. The programming platform detects the location and enhances the cell type protein expression in the patient's body to optimize the immunotherapy treatments.

Key facts about Strand Therapeutics

Founded Year: 2017
Location: Cambridge (United States)
Stage: Series B
Total Funding till date: $256M
Employee Count: 119 as on Mar 31, 2026
Investors: Kinnevik, Alexandria and 19 Others
Latest Funding Round: Series B, May 23, 2025, $*****
Highlight: Editors' Pick

4. Holmusk

AI-based digital health solutions and data analytics for providers. The platform NeuroBlu monitors the user's data and the prediction engine recommends lifestyle changes before the condition worsens. The proprietary analytical tools work on real-world data to recognize disease progression. The EHR system is designed to capture and monitor decisions and is combined with past mental health records. It also enables data-driven research and development providing evidence for regulatory submission.

Key facts about Holmusk

Founded Year: 2015
Location: Singapore (Singapore)
Annual Revenue: 2.28M SGD as on Mar 31, 2020
Last Known Valuation: $*****
Stage: Acquired
Total Funding till date: $109M
Employee Count: 189 as on Jul 01, 2024
Investors: Optum Ventures, Start2 and 37 Others
Latest Funding Round: Series B, Oct 12, 2023, $*****
Highlight: Acquired

5. MIT

Key facts about MIT

Founded Year: 1861
Location: United States
Stage: Seed
Total Funding till date: $4M
Employee Count: 11,888 as on Dec 31, 2022
Investors: Amgen Business Development, DOE and 19 Others
Latest Funding Round: Grant (prize money), Jun 17, 2025, $*****

View the full list of portfolio companies

Its most recent first time investment was in Syndesi Therapeutics.

View all investments by JLABS

JLABS has made 1 investment in Series A stage with an average round size of $21.1M.

View all investments by JLABS

JLABS has a portfolio focused on Life Sciences. Notably, it has invested in 299 Tech companies, 274 Enterprise (B2B) companies, 99 Software companies and at least 53 companies focusing on Tech hardware.

View all investments by JLABS

JLABS has made most investments in Belgium (1).

View all investments by JLABS

JLABS has not made any investment in 2026 so far.

Here are the most recent investments by JLABS:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Feb 01, 2018	Syndesi Therapeutics	Belgium	Series A	1226	Novo Holdings [+4]

See more recent investments made by JLABS

JLABS has 1 unicorn in its portfolio - Mammoth. The most recent unicorn in their portfolio is Mammoth which became a unicorn in 2021, 4 years before JLABS first invested in it.

Here is a list of unicorns in JLABS's portfolio:

Filter this list

Tracxn Score	Company	Short Description	Founded year	Sector	Location	Company Stage	First Investment/ Acquisition Details
65	Mammoth	Provider of molecular diagnostics platform by using CRISPR technology	2017	Life Sciences [+2]	Brisbane	Series D	piyqxof

View more details about unicorns in JLABS's portfolio

17 of JLABS's portfolio companies have become public. In Silico got listed on the Hong Kong Exchanges (HKG), in Dec 2025 at marketcap of $1.72B and Neurogene got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).

Here are JLABS's portfolio companies that went public:

Filter this list

Company	IPO Date	First Invested on	First Round of Investment	Round Size
In Silico	Dec 30, 2025	-	-	9738
Neurogene	Dec 19, 2023	-	-	8309
Tyra	Sep 15, 2021	-	-	2814
CARsgen	Jun 18, 2021	-	-	1413
NetraMark	Jun 07, 2021	-	-	2726

View more details about public companies in JLABS's portfolio

31 companies from JLABS's portfolio have been acquired. The most recent acquisition were Mitokinin in Oct 2023 by AbbVie for $110M.

Here are JLABS's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Mitokinin	Oct 05, 2023	-	-	4405
Glympse Bio	Aug 09, 2023	-	-	5178
Pionyr Immuntherapeutics	Aug 07, 2023	-	-	6842
Spindle Biotech	Jul 13, 2023	-	-	7155
Cyclica	May 08, 2023	-	-	3343

View all acquired companies in JLABS's portfolio

JLABS has a team of 10 members including 1 Partner and 7 Principals located in United States, Singapore and 2 more locations. JLABS's team does not sit on the board of any company as of now.

Here is a list of all team members in JLABS:

Name	Designation	Location	Board Memberships	Contact Details
Melinda Richter	Partner	-	-	-
Paul Englert	Principal	San Diego	-	-
Arjun Suresh	Principal	San Francisco	-	-
Alessandro Falcone	Principal	United Kingdom	-	-
Sravanthy Manesh	Principal	Singapore	-	-
Jenny Oan	Principal	Singapore	-	-
Bibiana Brame	Principal	Baltimore	-	-
Krishan Newman	Principal	Ajax	-	-